Trillium Therapeutics Inc (TRIL.CA) Stock Price, Forecast & Analysis
Canada - Toronto Stock Exchange - TSX:TRIL -
TRIL.CA Key Statistics, Chart & Performance
The current stock price of TRIL.CA is 23.33 null. In the past month the price increased by 5.33%.
TRIL.CA Latest News, Press Relases and Analysis
TRIL.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 445.72M | ||
| EDT.CA | SPECTRAL MEDICAL INC | N/A | 368.56M | ||
| HBP.CA | HELIX BIOPHARMA CORP | N/A | 177.20M | ||
| MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 128.45M | ||
| COV.CA | COVALON TECHNOLOGIES LTD | 24 | 52.65M | ||
| MBX.CA | MICROBIX BIOSYSTEMS INC | N/A | 34.18M | ||
| RVX.CA | RESVERLOGIX CORP | N/A | 31.54M | ||
| BCT.CA | BRIACELL THERAPEUTICS CORP | N/A | 27.20M | ||
| HEM.CA | HEMOSTEMIX INC | N/A | 16.56M | ||
| MPH.CA | MEDICURE INC | N/A | 11.48M | ||
| CSCI.CA | COSCIENS BIOPHARMA INC | N/A | 10.69M | ||
| QPT.CA | QUEST PHARMATECH INC | N/A | 6.77M |
Related stock screener links
About TRIL.CA
Company Profile
Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. The company is headquartered in Mississauga, Ontario and currently employs 33 full-time employees. The company went IPO on 2005-01-11. The firm is engaged in developing therapies for the treatment of cancer. The firm is developing two clinical programs, TTI-621 and TTI-622, target CD47, a don’t eat me signal that blocks the ability of macrophages to phagocytose and destroy tumor cells. The TTI-621 is being evaluated in a multicenter, open-label phase I trial in patients with relapsed/refractory hematologic malignancies. The TTI-622 is Trillium’s second SIRPαFc fusion protein. TTI-622 consists of the same extracellular CD47-binding domain of human SIRPα as TTI-621 but has an immunoglobulin G4 (IgG4) Fc region instead of an IgG1 Fc. TTI-622 is being studied in a two-part, multicenter, open-label, phase Ia/Ib study in patients with advanced relapsed or refractory lymphoma or multiple myeloma (NCT03530683). The company focuses on developing inhibitors of CD47, a checkpoint of the innate immune system.
Company Info
Trillium Therapeutics Inc
2488 Dunwin Drive
Mississauga ONTARIO 02140 CA
CEO: Jan Skvarka
Employees: 33
Phone: 14165950627.0
Trillium Therapeutics Inc / TRIL.CA FAQ
What does Trillium Therapeutics Inc do?
Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. The company is headquartered in Mississauga, Ontario and currently employs 33 full-time employees. The company went IPO on 2005-01-11. The firm is engaged in developing therapies for the treatment of cancer. The firm is developing two clinical programs, TTI-621 and TTI-622, target CD47, a don’t eat me signal that blocks the ability of macrophages to phagocytose and destroy tumor cells. The TTI-621 is being evaluated in a multicenter, open-label phase I trial in patients with relapsed/refractory hematologic malignancies. The TTI-622 is Trillium’s second SIRPαFc fusion protein. TTI-622 consists of the same extracellular CD47-binding domain of human SIRPα as TTI-621 but has an immunoglobulin G4 (IgG4) Fc region instead of an IgG1 Fc. TTI-622 is being studied in a two-part, multicenter, open-label, phase Ia/Ib study in patients with advanced relapsed or refractory lymphoma or multiple myeloma (NCT03530683). The company focuses on developing inhibitors of CD47, a checkpoint of the innate immune system.
What is the stock price of Trillium Therapeutics Inc today?
The current stock price of TRIL.CA is 23.33 null. The price increased by 0.47% in the last trading session.
What is the dividend status of Trillium Therapeutics Inc?
TRIL.CA does not pay a dividend.
How is the ChartMill rating for Trillium Therapeutics Inc?
TRIL.CA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists TRIL stock?
TRIL.CA stock is listed on the Toronto Stock Exchange exchange.
How is the valuation of Trillium Therapeutics Inc (TRIL.CA) based on its PE ratio?
Trillium Therapeutics Inc (TRIL.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.01).
TRIL.CA Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to TRIL.CA. When comparing the yearly performance of all stocks, TRIL.CA is one of the better performing stocks in the market, outperforming 93.21% of all stocks.
TRIL.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TRIL.CA. While TRIL.CA has a great health rating, there are worries on its profitability.
TRIL.CA Financial Highlights
Over the last trailing twelve months TRIL.CA reported a non-GAAP Earnings per Share(EPS) of -1.01. The EPS increased by 52.93% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -139737.5% | ||
| ROA | -21.06% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
TRIL.CA Forecast & Estimates
10 analysts have analysed TRIL.CA and the average price target is 18.87 null. This implies a price decrease of -19.12% is expected in the next year compared to the current price of 23.33.
For the next year, analysts expect an EPS growth of -9.05% and a revenue growth -96.9% for TRIL.CA